TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 06/01/2025 at 19:15, 6 months 3 days ago

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Transgene and NEC reveal positive data on TG4050 cancer vaccine, demonstrating durable disease-free survival and sustained T cell responses at 24 months in HPV-negative head and neck cancer. Conference call on June 6, 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 NEC
BRIEF

published on 05/22/2025 at 17:50, 6 months 13 days ago

Transgene to Present Phase I Data on Cancer Vaccine TG4050 at ASCO 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 Phase I Data
PRESS RELEASE

published on 05/22/2025 at 17:45, 6 months 13 days ago

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Transgene to present 24-month disease-free survival data from all patients in Phase I part of trial of individualized cancer vaccine, TG4050, at ASCO 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 Disease-free Survival
BRIEF

published on 04/10/2025 at 20:20, 7 months 24 days ago

Transgene makes available the 2024 Universal Registration Document

AMF Social Responsibility Immunotherapy Registration Document Transgene
PRESS RELEASE

published on 04/10/2025 at 20:15, 7 months 24 days ago

Availability of Transgene’s 2024 Universal Registration Document (URD)
Transgene announces availability of its 2024 Universal Registration Document (URD) containing financial reports and ESG factors. French & English versions can be accessed online

Financial Reports Transgene ESG Factors 2024 Universal Registration Document French Version
BRIEF

published on 03/27/2025 at 17:50, 8 months 8 days ago

Transgene: major advances and outlook for 2025

Immunotherapy Head And Neck Cancer 2024 Financial Results TG4050 Vaccine Myvac® Platform
PRESS RELEASE

published on 03/27/2025 at 17:45, 8 months 8 days ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 10 months 14 days ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 10 months 14 days ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 1 year ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 42 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 47 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 17 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 12 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 17 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 17 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 46 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 26 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 51 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 2 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 17 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 32 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 33 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE